Breaking News Instant updates and real-time market news.

GILD

Gilead

$74.87

0.33 (0.44%)

04:55
11/30/16
11/30
04:55
11/30/16
04:55

Gilead management to meet with Leerink

Meeting to be held in New York on November 30 hosted by Leerink.

  • 30

    Nov

  • 01

    Dec

  • 02

    Dec

  • 03

    Dec

GILD Gilead
$74.87

0.33 (0.44%)

11/17/16
LEER
11/17/16
NO CHANGE
Target $89
LEER
Market Perform
Gilead myelofibrosis data miss may open path for M&A, says Leerink
Leerink analyst Geoffrey Porges notes that Gilead (GILD) released disappointing Phase III data for its JAK 1/2 inhibitor momelotinib in myelofibrosis. The company indicated that they plan to discuss these results with regulatory authorities to determine the next steps, but it seems likely that momelotinib will be written off, he adds. However, Porges believes that this disappointment restores Incyte (INCY) to the list of feasible candidates for acquisition by Gilead, since it would no longer face the obligation to divest one of the overlapping JAK programs. He reiterates a Market Perform rating and $89 price target on Gilead's shares.
11/17/16
LEER
11/17/16
NO CHANGE
Target $115
LEER
Outperform
Incyte price target raised to $115 from $101 at Leerink
Leerink analyst Michael Schmidt raised his price target for Incyte (INCY) to $115 from $101 after Gilead (GILD) reported disappointing top-line results from two Phase III studies evaluating momelotinib, its JAK1/2 inhibitor for patients with myelofibrosis. The analyst believes that the removal of this uncertainty on the revenue outlook of Incyte's key commercial product, combined with increasing prospects of a repatriation holiday should make the company more attractive as an acquisition target. He reiterates an Outperform rating on Incyte's shares.
11/17/16
BMOC
11/17/16
NO CHANGE
BMOC
Incyte drug won't have 'meaningful competition,' says BMO Capital
BMO Capital analyst M. Ian Somaiya says that "mixed data" on Gilead's (GILD) momelotinib in myelofibrosis eliminates any "meaningful competition" faced by Incyte's (INCY) Jakafi in the disease. The analyst raised his price target on Incyte to $126 from $121 and keeps an Outperform rating on the shares.
11/18/16
GABE
11/18/16
NO CHANGE
Target $99
GABE
Buy
Incyte, Regeneron among Gilead M&A options after latest setback, says Gabelli
Gabelli analyst Jing He noted Gilead's (GILD) "mixed" results from its Phase III trials evaluating momelotinib, which showed that the drug is not superior to Incyte's (INCY) Jakafi. Commenting on Gilead's potential path after momelotinib's "disappointing" results and several other pipeline setbacks this year, He suggested that Gilead could look to buy Incyte, which looks like "Regeneron lite," or simply buy Regeneron (REGN) itself. The analyst said Gilead could alternately target an orphan drug company such as Alexion (ALXN), Vertex (VRTX) or BioMarin (BMRN). She keeps a Buy rating and $99 per share private market value on Gilead shares, as she expects M&A to be a catalyst for the stock.

TODAY'S FREE FLY STORIES

GE

General Electric

$18.14

-0.625 (-3.33%)

10:40
01/16/18
01/16
10:40
01/16/18
10:40
Periodicals
GE seen as likely to embrace company breakup, CNBC reports »

General Electric is seen…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 24

    Jan

HMNY

Helios and Matheson

$7.64

-0.42 (-5.21%)

10:40
01/16/18
01/16
10:40
01/16/18
10:40
Hot Stocks
MoviePass names Natasha Mulla CMO »

MoviePass, movie-theater…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EEM

MSCI Emerging Markets Index

$49.79

0.275 (0.56%)

10:40
01/16/18
01/16
10:40
01/16/18
10:40
Options
Notable interest in iShares Emerging Markets Fund options »

Notable interest in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

C

Citi

$77.54

0.695 (0.90%)

10:38
01/16/18
01/16
10:38
01/16/18
10:38
Hot Stocks
Citi CFO says U.S. Retail Services growing slightly above outlook »

CFO John Gerspach said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 24

    Jan

VPG

Vishay Precision

$27.30

0.55 (2.06%)

10:38
01/16/18
01/16
10:38
01/16/18
10:38
Conference/Events
Vishay Precision management to meet with Sidoti »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 17

    Jan

  • 29

    Mar

SITE

SiteOne Landscape

$71.28

-0.2 (-0.28%)

10:37
01/16/18
01/16
10:37
01/16/18
10:37
Conference/Events
SiteOne Landscape management to meet with William Blair »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 17

    Jan

  • 18

    Jan

IWM

iShares Trust Russell 2000 Index Fund

$159.21

1.05 (0.66%)

, RUT

Russell 2000 Index

10:36
01/16/18
01/16
10:36
01/16/18
10:36
Technical Analysis
Technical View: Russell 2000 Index crosses above 1600, new life high »

The Russell 2000 (RUT)…

IWM

iShares Trust Russell 2000 Index Fund

$159.21

1.05 (0.66%)

RUT

Russell 2000 Index

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LPTH

LightPath

$2.42

0.09 (3.86%)

10:36
01/16/18
01/16
10:36
01/16/18
10:36
Conference/Events
LightPath management to meet with Roth Capital »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

LOW

Lowe's

$104.00

3.14 (3.11%)

10:35
01/16/18
01/16
10:35
01/16/18
10:35
Conference/Events
Lowe's management to meet with UBS »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Feb

GE

General Electric

$18.17

-0.595 (-3.17%)

10:35
01/16/18
01/16
10:35
01/16/18
10:35
Periodicals
GE breakup likely, announcement may come this Spring, CNBC reports »

CNBC's David Faber…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 24

    Jan

C

Citi

$77.56

0.715 (0.93%)

10:33
01/16/18
01/16
10:33
01/16/18
10:33
Hot Stocks
Breaking Hot Stocks news story on Citi »

Citi CFO: Trading-related…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 24

    Jan

10:33
01/16/18
01/16
10:33
01/16/18
10:33
Conference/Events
UBS leisure analyst holds an analyst/industry conference call »

Leisure Analyst Farley…

ITRN

Ituran

$35.30

1.25 (3.67%)

10:33
01/16/18
01/16
10:33
01/16/18
10:33
Conference/Events
Ituran management to meet with Jefferies »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 17

    Jan

  • 17

    Jan

C

Citi

$77.50

0.66 (0.86%)

10:33
01/16/18
01/16
10:33
01/16/18
10:33
Hot Stocks
Breaking Hot Stocks news story on Citi »

Citi sees core accrual…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 24

    Jan

AXTA

Axalta Coating

$31.99

-0.45 (-1.39%)

, UBS

UBS

$19.62

0.03 (0.15%)

10:32
01/16/18
01/16
10:32
01/16/18
10:32
Initiation
On The Fly: Top five analyst initiations »

Catch up on today's…click here.

AXTA

Axalta Coating

$31.99

-0.45 (-1.39%)

UBS

UBS

$19.62

0.03 (0.15%)

CS

Credit Suisse

$19.04

0.08 (0.42%)

NTR

Nutrien

$53.31

-0.12 (-0.22%)

CBM

Cambrex

$52.80

1.15 (2.23%)

DRNA

Dicerna

$8.42

-0.01 (-0.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

UA

Under Armour; also tag UAA

$13.13

-1.01 (-7.14%)

, UAA

Under Armour; also tag UA

$14.21

-0.91 (-6.02%)

10:32
01/16/18
01/16
10:32
01/16/18
10:32
Downgrade
On The Fly: Top five analyst downgrades »

Catch up on today's…click here.

UA

Under Armour; also tag UAA

$13.13

-1.01 (-7.14%)

UAA

Under Armour; also tag UA

$14.21

-0.91 (-6.02%)

VZ

Verizon

$51.84

-0.023 (-0.04%)

LMT

Lockheed Martin

$336.31

0.06 (0.02%)

COL

Rockwell Collins

$138.14

0.31 (0.22%)

SAVE

Spirit Airlines

$47.19

-1.07 (-2.22%)

FNSR

Finisar

$22.74

0.48 (2.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 01

    Feb

  • 21

    Feb

  • 07

    Mar

QCOM

Qualcomm

$65.38

-0.05 (-0.08%)

, TWTR

Twitter

$24.88

-0.535 (-2.11%)

10:32
01/16/18
01/16
10:32
01/16/18
10:32
Upgrade
On The Fly: Top five analyst upgrades »

Catch up on today's…click here.

QCOM

Qualcomm

$65.38

-0.05 (-0.08%)

TWTR

Twitter

$24.88

-0.535 (-2.11%)

PG

Procter & Gamble

$90.31

0.7 (0.78%)

NOC

Northrop Grumman

$317.94

2.79 (0.89%)

CW

Curtiss-Wright

$133.63

4.893 (3.80%)

ADTN

Adtran

CIEN

Ciena

$22.69

0.75 (3.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 17

    Jan

  • 17

    Jan

  • 23

    Jan

  • 23

    Jan

  • 25

    Jan

  • 07

    Feb

  • 08

    Feb

  • 16

    Feb

  • 21

    Feb

  • 22

    Feb

  • 06

    Mar

TWTR

Twitter

$24.85

-0.565 (-2.22%)

10:32
01/16/18
01/16
10:32
01/16/18
10:32
Periodicals
Greenlight took 'small' stake in Twitter in Q4, Bloomberg reports »

Bloomberg cites…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 23

    Jan

  • 07

    Feb

  • 08

    Feb

XLF

Financial Select Sector

$29.38

0.15 (0.51%)

10:30
01/16/18
01/16
10:30
01/16/18
10:30
Options
Notable spread in SPDR Financials as the sector sees strength »

Notable spread in SPDR…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:29
01/16/18
01/16
10:29
01/16/18
10:29
Conference/Events
UBS automotive analyst holds an analyst/industry conference call »

Automotive Analyst Hummel…

10:28
01/16/18
01/16
10:28
01/16/18
10:28
General news
Tax reform optimism, Merck help push Dow up 1% to over 26,000 »

Stock futures were strong…

C

Citi

$77.60

0.76 (0.99%)

10:27
01/16/18
01/16
10:27
01/16/18
10:27
Hot Stocks
Citi CFO sees branded-cards NCL rate rising to 300bps in 2018 »

Says adjusting strategy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 24

    Jan

CF

CF Industries

$41.63

-1.8919 (-4.35%)

10:26
01/16/18
01/16
10:26
01/16/18
10:26
Technical Analysis
Technical View: CF Industries falls sharply to session lows »

The stock was last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:25
01/16/18
01/16
10:25
01/16/18
10:25
General news
U.S. corporate bond update: moderate issuance is expected »

U.S. corporate bond…

10:25
01/16/18
01/16
10:25
01/16/18
10:25
Conference/Events
BMO Capital specialty pharma analyst holds analyst/industry conference call »

Specialty Pharmaceutical…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.